CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Dan Passeri

Former CEO, Cue Biopharma

Search every verified Dan Passeri interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In September 2023, Dan Passeri, then CEO of Cue Biopharma, appeared on the Business of Biotech podcast alongside the company's President and CSO, Anish Suri, Ph.D. During the conversation, Passeri discussed the company's progress in advancing multiple clinical candidates, noting that Cue Biopharma had completed phase one monotherapy trials for one candidate. He explained the strategic importance of demonstrating single-agent activity before pursuing combination studies, citing the need to establish a statistical spread with a smaller patient population. Passeri also addressed the company's approach to IL-2 therapy, describing the historical use of indiscriminate IL-2 injections as an "absurd premise" due to the receptor's presence across multiple cell types. He highlighted Cue Biopharma's discretely targeted IL-2 approach as a more deliberate strategy. Additionally, Passeri mentioned the company's productive relationship with the FDA, citing an example where the agency approved an IND for a second clinical candidate after Cue Biopharma demonstrated that two of its candidates were 99% sequence identical, differing only in T-cell specificity. He also reflected on leveraging his legal background in his daily work as CEO.

Recent appearances

  • Vested Interests Episode 1- Cue Biopharma- Nasdaq: CUE

    May 17, 2024 · 📺 MDB Capital Community

    MDB Capital President & Chief Market Strategist Lou Basenese sat down in Boston with Cue Biopharma, Inc.’s (Nasdaq: CUE) CEO Dan Passeri and President & Chief Scientific Officer Anish Suri to discuss the company’s latest developments and what it’s doing to lead a new revolution in cancer treatments. IMPORTANT DISCLOSURES: This message and video and any attachments are intended only for the use of the addressee and may contain confidential, proprietary and/or privileged information. If you are not the intended recipient, any review, use, distribution, dissemination or copying of this email is…

    Watch on YouTube ↗

  • Clinical Leadership with Cue Biopharma's Anish Suri, Ph.D. & Dan Passeri, J.D.

    October 23, 2023 · 📺 Life Science Connect

    On a road trip to Boston, the Business of Biotech caught up with podcast alum Dan Passeri, J.D., CEO at Cue Biopharma, and enjoyed a two-for-one with CSO and President Anish Suri, Ph.D. at Cue's headquarters just feet below the Auerbach Center. Among other things, we discussed the duo's complementary leadership approach as the company takes multiple candidates into the clinic, why Passeri leans into his biotech legal background almost every day he's at work, why Cue's discretely targeted IL-2 approach eliminates the absurdity of early IL-2 failures, and a whole lot more. Speaking of Dan's leg…

    Watch on YouTube ↗

  • Cue Biopharma, Inc CUE CEO Dan Passeri on Q1 2020 Results

    May 20, 2020 · 📺 Daily Earnings Calls

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →